Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Cadence Pharmaceuticals, Inc. Stockholders
February 11 2014 - 4:30PM
Business Wire
Kirby McInerney LLP is investigating potential claims against
the Board of Directors of Cadence Pharmaceuticals, Inc. (“Cadence”
or the “Company”) (NASDAQ: CADX) concerning the proposed
acquisition of the Company by Mallinckrodt plc (“Mallinckrodt”)
(NYSE: MNK). Under the terms of the definitive merger agreement,
Cadence stockholders will receive $14.00 in cash for each share of
Cadence owned, valuing the transaction at approximately $1.3
billion on a fully diluted basis.
The investigation concerns whether the Cadence Board of
Directors violated its fiduciary duties by agreeing to the proposed
transaction and whether the proposed consideration adequately
values Cadence’s common stock.
If you are a Cadence stockholder and wish to obtain additional
information, please contact J. Brandon Walker, Esq. by email
at bwalker@kmllp.com, by telephone at (212) 699-1145 or (888)
529-4787, or by filling out this contact form. There is no cost or
obligation to you.
Kirby McInerney LLP is a New York-based law firm concentrating
in securities, shareholder, whistleblower, antitrust and consumer
litigation. For additional information, please go to
www.kmllp.com.
Kirby McInerney LLPJ. Brandon Walker, Esq.(212) 699-1145 or
(888) 529-4787bwalker@kmllp.com
(MM) (NASDAQ:CADX)
Historical Stock Chart
From Mar 2024 to Apr 2024
(MM) (NASDAQ:CADX)
Historical Stock Chart
From Apr 2023 to Apr 2024
